Hydroxychloroquine- and Azithromycin-Induced Transient Left-Bundle Branch Block in a Patient with COVID-19

Layal Mansour, Soha Fakhreddine, M. Saliba, S. Kabbani
{"title":"Hydroxychloroquine- and Azithromycin-Induced \nTransient Left-Bundle Branch Block in a Patient with \nCOVID-19","authors":"Layal Mansour, Soha Fakhreddine, M. Saliba, S. Kabbani","doi":"10.33590/emjcardiol/20-00246","DOIUrl":null,"url":null,"abstract":"Background: COVID-19 has emerged and rapidly spread worldwide due to the high infectivity of the novel coronavirus. A new regimen consisting of a combination of hydroxychloroquine and azithromycin has been under evaluation for efficacy and side effects, especially cardiotoxicity.\n\nCase summary: A 58-year-old man was admitted to the hospital for COVID-19 pneumonia. His initial ECG showed sinus tachycardia. He was started on combination therapy of azithromycin and hydroxychloroquine. After the second dose of hydroxychloroquine and initial dose of azithromycin, his ECG showed complete left-bundle branch block (LBBB). The treatment was stopped, and the patient had no cardiac symptoms. On Day 8 of admission, his repeat ECG showed an absence of LBBB.\n\nDiscussion: The cumulative dose of hydroxychloroquine observed in patients treated for malaria or systemic diseases is cardiotoxic, and few cases of LBBB, have been reported. It is, however, not known whether the use of azithromycin in association with a small dose of hydroxychloroquine induces transient LBBB.","PeriodicalId":284912,"journal":{"name":"EMJ Cardiology","volume":"13 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMJ Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33590/emjcardiol/20-00246","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: COVID-19 has emerged and rapidly spread worldwide due to the high infectivity of the novel coronavirus. A new regimen consisting of a combination of hydroxychloroquine and azithromycin has been under evaluation for efficacy and side effects, especially cardiotoxicity. Case summary: A 58-year-old man was admitted to the hospital for COVID-19 pneumonia. His initial ECG showed sinus tachycardia. He was started on combination therapy of azithromycin and hydroxychloroquine. After the second dose of hydroxychloroquine and initial dose of azithromycin, his ECG showed complete left-bundle branch block (LBBB). The treatment was stopped, and the patient had no cardiac symptoms. On Day 8 of admission, his repeat ECG showed an absence of LBBB. Discussion: The cumulative dose of hydroxychloroquine observed in patients treated for malaria or systemic diseases is cardiotoxic, and few cases of LBBB, have been reported. It is, however, not known whether the use of azithromycin in association with a small dose of hydroxychloroquine induces transient LBBB.
羟氯喹和阿奇霉素致COVID-19患者短暂性左束支传导阻滞
背景:由于新型冠状病毒的高传染性,COVID-19已在全球范围内出现并迅速传播。一种由羟氯喹和阿奇霉素联合组成的新方案正在评估其疗效和副作用,特别是心脏毒性。病例总结:一名58岁男性因COVID-19肺炎住院。他最初的心电图显示窦性心动过速。他开始了阿奇霉素和羟氯喹的联合治疗。在第二次羟氯喹和第一次阿奇霉素治疗后,他的心电图显示完全左束分支阻滞(LBBB)。治疗停止,病人没有心脏症状。入院第8天复查心电图显示无LBBB。讨论:在治疗疟疾或全系统疾病的患者中观察到羟基氯喹的累积剂量是心脏毒性的,并且很少有LBBB病例的报道。然而,目前尚不清楚阿奇霉素与小剂量羟氯喹联合使用是否会诱发短暂性LBBB。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信